FDA Clearance Tracker · K922906
AMPLICOR CHLAMYDIA TRACHOMATIS TEST
Last checked: Nov 20, 2026Latest source record: Jun 15, 1993 (this decision)Source: openFDAMethods & limitations
Decided
Jun 15, 1993
Substantially Equivalent
Time to decision
363 days
Received Jun 17, 1992. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class I
The decision
- FDA number
- K922906
- Device name
- AMPLICOR CHLAMYDIA TRACHOMATIS TEST
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Branchburg, NJ
- Received
- Jun 17, 1992
- Decided
- Jun 15, 1993
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class I
- Regulation
- 21 CFR 866.3120
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code MKZ (Dna Probe, Nucleic Acid Amplification, Chlamydia).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K922906
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.